Hinova Pharmaceuticals Inc. (SHA:688302)

Hinova Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	397.92	633.44	813.23	1,202	901.22	1,139
Trading Asset Securities	410.75	210.49	290.62	366.24	-	-
Cash & Short-Term Investments	917.05	843.93	1,104	1,568	901.22	1,139
Cash Growth	0.85%	-23.55%	-29.59%	73.97%	-20.85%	4801.37%
Other Receivables	0.66	0.84	1.39	1.67	0.54	0.14
Receivables	7.16	0.84	1.39	1.67	0.54	0.14
Inventory	0.73	0	0.01	0.01	0	0
Prepaid Expenses	-	-	-	-	13.09	-
Other Current Assets	50.5	40.77	41.99	41.78	40.38	43.67
Total Current Assets	975.44	885.54	1,147	1,611	955.24	1,182
Property, Plant & Equipment	342.47	328.62	187.99	86.61	12.72	4.27
Long-Term Investments	9.55	113.09	109.98	5	-	-
Other Intangible Assets	31.26	30.56	31.21	31.86	-	-
Long-Term Deferred Charges	-	-	0.04	0.08	-	0.63
Other Long-Term Assets	4.46	3.77	15.12	0.21	14.39	0.59
Total Assets	1,363	1,362	1,492	1,735	982.35	1,188
Accounts Payable	110.24	40.63	3.14	2.29	1.31	52.66
Accrued Expenses	7.62	31.09	49.17	69.81	90.45	4.93
Short-Term Debt	-	-	-	30	-	0.5
Current Portion of Leases	3.27	3.22	3.77	2.45	2.8	-
Current Income Taxes Payable	1.67	-	-	-	-	0.2
Other Current Liabilities	18.41	72.01	50.76	33.73	96.77	141
Total Current Liabilities	141.35	146.95	106.84	138.27	191.33	199.29
Long-Term Leases	3.41	5.83	9.08	3.31	1.11	-
Long-Term Unearned Revenue	17.51	16.55	8.55	8.1	1.15	2.45
Total Liabilities	262.27	169.33	124.47	149.68	193.59	201.74
Common Stock	99.02	99.02	99.02	99.02	74.26	74.26
Additional Paid-In Capital	2,591	2,583	2,558	2,482	1,409	1,300
Retained Earnings	-1,589	-1,490	-1,290	-996.06	-694.54	-388.36
Comprehensive Income & Other	-0.1	-0.03	0.11	0.14	-0.07	-0.04
Total Common Equity	1,101	1,192	1,367	1,585	788.76	986.15
Shareholders' Equity	1,101	1,192	1,367	1,585	788.76	986.15
Total Liabilities & Equity	1,363	1,362	1,492	1,735	982.35	1,188
Total Debt	106.67	9.05	12.85	35.76	3.91	0.5
Net Cash (Debt)	810.38	834.88	1,091	1,532	897.31	1,138
Net Cash Growth	-9.89%	-23.48%	-28.79%	70.74%	-21.16%	6142.95%
Net Cash Per Share	8.14	8.41	11.02	16.87	12.07	16.19
Filing Date Shares Outstanding	99.02	99.02	99.02	99.02	74.26	74.26
Total Common Shares Outstanding	99.02	99.02	99.02	99.02	74.26	74.26
Working Capital	834.09	738.59	1,040	1,473	763.91	983.11
Book Value Per Share	11.12	12.04	13.81	16.01	10.62	13.28
Tangible Book Value	1,070	1,162	1,336	1,554	788.76	986.15
Tangible Book Value Per Share	10.80	11.73	13.49	15.69	10.62	13.28
Machinery	-	17.15	15.49	14.85	11.16	8.69
Construction In Progress	-	314.5	169.54	73.76	3	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.